| Literature DB >> 23171620 |
Matthew Dicicco1, Suresh Neethirajan, Ameet Singh, J Scott Weese.
Abstract
BACKGROUND: Surgical site infections (SSIs) caused by biofilm-forming methicillin-resistant Staphylococcus pseudintermedius (MRSP) have emerged as the most common hospital-acquired infections in companion animals. No methods currently exist for the therapeutic remediation of SSIs caused by MRSP in biofilms. Clarithromycin (CLA) has been shown to prevent biofilm formation by Staphylococcus aureus. This study aims to assess the in vitro activity of CLA in eradicating MRSP biofilm formation on various materials.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23171620 PMCID: PMC3534386 DOI: 10.1186/1746-6148-8-225
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Figure 1Effect of Clarithromycin on MRSP after 24 h. Biofilm forming potential of 20 MRSP strains and the effect of clarithromycin after 24 h as revealed by Crystal Violet Microtiter Assay. Mean OD570 +/− SD of the MRSP isolates with and without clarithromycin were 1.0 +/− 0.63 and 1.1 +/− 0.59, respectively. Clarithromycin had no significant effect (P = 0.5126) on MRSP biofilm formation.
Origin, biofilm adherence classification, direct repeat unit (dru) and sequence type of study isolates
| A3 | LOW | 9a | 71 | U.S.A |
| A12 | STRONG | 10h | 68 | U.S.A |
| A23 | STRONG | 10a | 68 | U.S.A |
| A46 | MODERATE | 9a | 71 | U.S.A |
| A56 | LOW | 9a | 71 | U.S.A |
| A92 | MODERATE | 9a | 71 | U.S.A |
| SP87 | LOW | 9a | 71 | Canada |
| SP88 | LOW | 9a | 71 | Canada |
| SP90 | STRONG | 9a | 71 | Canada |
| SP91 | LOW | 9a | 71 | Canada |
| SP93 | LOW | 9a | 71 | Canada |
| SP102 | LOW | 11a | 68 | Canada |
| SP104 | MODERATE | 10h | 68 | Canada |
| SP105 | MODERATE | 10h | 68 | Canada |
| SP106 | MODERATE | 9a | 71 | Canada |
| SP112 | MODERATE | 9a | 71 | Canada |
| SP113 | MODERATE | 9a | 71 | Canada |
| SP114 | LOW | 9a | 71 | Canada |
| SP115 | LOW | 9a | 71 | Canada |
| SP116 | LOW | 9a | 71 | Canada |
Dru typing of chosen biofilm forming isolates of MRSP reveals a representative population of strains commonly found in veterinary hospitals across North America. Adherence capabilities were determined based on the model developed by Stepanovic et al., 2000.
Figure 2Effect of Clarithromycin on MRSP over time. Biofilm forming potential of MRSP A12 strain and the effect of clarithromycin over time as revealed by Crystal Violet Microtiter Plate Assay. Clarithromycin had no significant effect on MRSP biofilm formation between 4 and 24 h.
Figure 3SEM images of biofilms formed on canine orthopaedic bone screws treated with addition of clarithromycin. (A) Showing minimal MRSP biofilm production at 4 h (B) showing increased EPS (extracellular polymeric substance) and morphological changes characteristic to biofilms at 12 h (C) firm attachment of MRSP biofilm, further increase of EPS and clumping of cells at 24 h (D) MRSP biofilm growth concentrated to specific areas on the screw head.
Figure 4SEM images of biofilm adherence around circular striations from machining on canine orthopaedic bone screws. (A) MRSP biofilm growth at 8 h without CLA addition (B) MRSP biofilm growth at 24 h without CLA addition.